|
US7312196B2
(en)
*
|
1997-01-08 |
2007-12-25 |
Amylin Pharmaceuticals, Inc. |
Formulations for amylin agonist peptides
|
|
WO2004037168A2
(en)
*
|
2002-10-18 |
2004-05-06 |
Amylin Pharmaceuticals, Inc. |
Treatment of pancreatitis with amylin
|
|
EP1663289A2
(en)
*
|
2003-08-29 |
2006-06-07 |
Amylin Pharmaceuticals, Inc. |
Methods for treating or ameliorating ghrelin-associated diseases and disorders
|
|
US20080318837A1
(en)
*
|
2003-12-26 |
2008-12-25 |
Nastech Pharmaceutical Company Inc. |
Pharmaceutical Formation For Increased Epithelial Permeability of Glucose-Regulating Peptide
|
|
WO2007065156A2
(en)
*
|
2005-12-02 |
2007-06-07 |
Nastech Pharmaceutical Company Inc. |
Pharmaceutical formulation for increased epithelial permeability of glucose-regulating peptide
|
|
US20050143303A1
(en)
*
|
2003-12-26 |
2005-06-30 |
Nastech Pharmaceutical Company Inc. |
Intranasal administration of glucose-regulating peptides
|
|
US20060210614A1
(en)
*
|
2003-12-26 |
2006-09-21 |
Nastech Pharmaceutical Company Inc. |
Method of treatment of a metabolic disease using intranasal administration of exendin peptide
|
|
US20060074025A1
(en)
*
|
2003-12-26 |
2006-04-06 |
Nastech Pharmaceutical Company Inc. |
Therapeutic formulations for transmucosal administration that increase glucagon-like peptide-1 bioavailability
|
|
ATE471340T1
(de)
*
|
2004-02-11 |
2010-07-15 |
Amylin Pharmaceuticals Inc |
Peptide der amylin familie, verfahren zu deren herstellung und verwendung
|
|
US7399744B2
(en)
*
|
2004-03-04 |
2008-07-15 |
Amylin Pharmaceuticals, Inc. |
Methods for affecting body composition
|
|
ES2633574T3
(es)
|
2005-03-25 |
2017-09-22 |
Regeneron Pharmaceuticals, Inc. |
Formulaciones de antagonistas de VEGF
|
|
CN102343084A
(zh)
|
2005-03-31 |
2012-02-08 |
安米林药品公司 |
用于治疗精神病和精神障碍的胰淀素和胰淀素激动剂
|
|
US20080318861A1
(en)
*
|
2005-12-08 |
2008-12-25 |
Nastech Pharmaceutical Company Inc. |
Mucosal Delivery of Stabilized Formulations of Exendin
|
|
EP1996224B1
(en)
*
|
2006-03-15 |
2012-11-07 |
Novo Nordisk A/S |
Mixtures of amylin and insulin
|
|
US7834050B2
(en)
|
2006-03-29 |
2010-11-16 |
Duke University |
Small molecule insulin mimetics absent quinones
|
|
CA2654510C
(en)
|
2006-06-16 |
2015-03-17 |
Regeneron Pharmaceuticals, Inc. |
Vegf antagonist formulations suitable for intravitreal administration
|
|
WO2008124522A2
(en)
*
|
2007-04-04 |
2008-10-16 |
Biodel, Inc. |
Amylin formulations
|
|
US20100222251A1
(en)
*
|
2007-09-11 |
2010-09-02 |
Novo Nordisk A/S |
Mixture comprising an amylin peptide and a protracted insulin
|
|
EP2036539A1
(en)
|
2007-09-11 |
2009-03-18 |
Novo Nordisk A/S |
Stable formulations of amylin and its analogues
|
|
EP2060268A1
(en)
*
|
2007-11-15 |
2009-05-20 |
Novo Nordisk A/S |
Pharmaceutical compositions for pulmonary or nasal delivery of peptides
|
|
EP2220115A2
(en)
*
|
2007-12-13 |
2010-08-25 |
Glaxo Group Limited |
Polypeptides, antibody variable domains & antagonists
|
|
MY152979A
(en)
|
2008-01-09 |
2014-12-15 |
Sanofi Aventis Deutschland |
Novel insulin derivatives having an extremely delayed time-action profile
|
|
EP2113253B1
(en)
*
|
2008-04-30 |
2010-03-31 |
Immatics Biotechnologies GmbH |
Novel formulations of tumour-associated peptides binding to human leukocyte antigen (HLA) class I or II molecules for vaccines
|
|
CA2724475C
(en)
*
|
2008-05-16 |
2019-05-07 |
The Children's Hospital Of Philadelphia |
Genetic alterations on chromosomes 21q, 6q and 15q and methods of use thereof for the diagnosis and treatment of type i diabetes
|
|
RS59913B1
(sr)
|
2008-10-17 |
2020-03-31 |
Sanofi Aventis Deutschland |
Kombinacija insulina i glp-1-agonista
|
|
US20130064834A1
(en)
|
2008-12-15 |
2013-03-14 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating hypercholesterolemia using antibodies to pcsk9
|
|
JO3672B1
(ar)
|
2008-12-15 |
2020-08-27 |
Regeneron Pharma |
أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
|
|
US9060927B2
(en)
|
2009-03-03 |
2015-06-23 |
Biodel Inc. |
Insulin formulations for rapid uptake
|
|
CN101822822A
(zh)
*
|
2009-03-04 |
2010-09-08 |
北京德众万全药物技术开发有限公司 |
一种普兰林肽的药物组合物及其制备方法
|
|
CA2755068C
(en)
|
2009-03-12 |
2018-11-06 |
Keybioscience Ag |
Treatment of diabetes and metabolic syndrome
|
|
CN102596175A
(zh)
|
2009-07-06 |
2012-07-18 |
赛诺菲-安万特德国有限公司 |
含有甲硫氨酸的水性胰岛素制备物
|
|
MY180661A
(en)
|
2009-11-13 |
2020-12-04 |
Sanofi Aventis Deutschland |
Pharmaceutical composition comprising a glp-1 agonist, an insulin and methionine
|
|
PT3345593T
(pt)
|
2009-11-13 |
2023-11-27 |
Sanofi Aventis Deutschland |
Composição farmacêutica compreendendo despro36exendina- 4(1-39)-lys6-nh2 e metionina
|
|
JO3417B1
(ar)
|
2010-01-08 |
2019-10-20 |
Regeneron Pharma |
الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
|
|
PL2611458T3
(pl)
|
2010-08-30 |
2017-02-28 |
Sanofi-Aventis Deutschland Gmbh |
Zastosowanie AVE0010 do produkcji leku do leczenia cukrzycy typu 2
|
|
CN102145164B
(zh)
*
|
2010-12-16 |
2013-02-27 |
深圳市健元医药科技有限公司 |
一种更加稳定的iapp类似物注射剂
|
|
SG192117A1
(en)
|
2011-01-28 |
2013-08-30 |
Sanofi Sa |
Human antibodies to pcsk9 for use in methods of treating particular groups of subjects
|
|
JO3283B1
(ar)
|
2011-04-26 |
2018-09-16 |
Sanofi Sa |
تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
|
|
US9821032B2
(en)
|
2011-05-13 |
2017-11-21 |
Sanofi-Aventis Deutschland Gmbh |
Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
|
|
WO2012170796A1
(en)
*
|
2011-06-09 |
2012-12-13 |
Amylin Pharmaceuticals, Inc. |
Gel compositions
|
|
AR087305A1
(es)
|
2011-07-28 |
2014-03-12 |
Regeneron Pharma |
Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
|
|
AR087693A1
(es)
|
2011-08-29 |
2014-04-09 |
Sanofi Aventis Deutschland |
Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2
|
|
TWI559929B
(en)
|
2011-09-01 |
2016-12-01 |
Sanofi Aventis Deutschland |
Pharmaceutical composition for use in the treatment of a neurodegenerative disease
|
|
HUE069234T2
(hu)
|
2011-09-16 |
2025-02-28 |
Regeneron Pharma |
Eljárások lipoprotein(a)-szint csökkentésére proprotein-konvertáz szubtilizin/kexin 9 (PCSK9) inhibitorának beadásával
|
|
TWI589299B
(zh)
|
2011-10-11 |
2017-07-01 |
再生元醫藥公司 |
用於治療類風濕性關節炎之組成物及其使用方法
|
|
KR102063028B1
(ko)
|
2012-01-23 |
2020-01-07 |
리제너론 파아마슈티컬스, 인크. |
항-ａｎｇ2 항체를 함유하는 안정화된 제형
|
|
WO2013177565A1
(en)
|
2012-05-25 |
2013-11-28 |
Amylin Pharmaceuticals, Llc |
Insulin-pramlintide compositions and methods for making and using them
|
|
AR092325A1
(es)
|
2012-05-31 |
2015-04-15 |
Regeneron Pharma |
Formulaciones estabilizadas que contienen anticuerpos anti-dll4 y kit
|
|
UA116217C2
(uk)
|
2012-10-09 |
2018-02-26 |
Санофі |
Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
|
|
AU2013366692B2
(en)
|
2012-12-21 |
2017-11-23 |
Sanofi |
Dual GLP1/GIP or trigonal GLP1/GIP/Glucagon agonists
|
|
US10111953B2
(en)
|
2013-05-30 |
2018-10-30 |
Regeneron Pharmaceuticals, Inc. |
Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
|
|
US10313682B2
(en)
*
|
2013-08-26 |
2019-06-04 |
Qualcomm Incorporated |
Determining regions when performing intra block copying
|
|
CN118105480A
(zh)
|
2013-11-12 |
2024-05-31 |
赛诺菲生物技术公司 |
用于与pcsk9抑制剂一起使用的给药方案
|
|
EP3080154B1
(en)
|
2013-12-13 |
2018-02-07 |
Sanofi |
Dual glp-1/gip receptor agonists
|
|
WO2015086728A1
(en)
|
2013-12-13 |
2015-06-18 |
Sanofi |
Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
|
|
EP3080152A1
(en)
|
2013-12-13 |
2016-10-19 |
Sanofi |
Non-acylated exendin-4 peptide analogues
|
|
WO2015086733A1
(en)
|
2013-12-13 |
2015-06-18 |
Sanofi |
Dual glp-1/glucagon receptor agonists
|
|
TW201625669A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
|
|
TW201625668A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
|
|
TW201625670A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
|
|
US9932381B2
(en)
|
2014-06-18 |
2018-04-03 |
Sanofi |
Exendin-4 derivatives as selective glucagon receptor agonists
|
|
US9656017B2
(en)
|
2014-06-20 |
2017-05-23 |
Howard E. Greene |
Infusion delivery devices and methods
|
|
KR20230074283A
(ko)
|
2014-07-16 |
2023-05-26 |
사노피 바이오테크놀로지 |
이형접합성 가족성 고콜레스테롤혈증(heFH) 환자의 치료방법
|
|
EA035674B1
(ru)
|
2014-07-18 |
2020-07-24 |
Санофи |
Способ определения того, является ли пациент, предположительно страдающий от рака, кандидатом для терапии афлиберцептом
|
|
EP3229828B1
(en)
|
2014-12-12 |
2023-04-05 |
Sanofi-Aventis Deutschland GmbH |
Insulin glargine/lixisenatide fixed ratio formulation
|
|
TWI748945B
(zh)
|
2015-03-13 |
2021-12-11 |
德商賽諾菲阿凡提斯德意志有限公司 |
第２型糖尿病病患治療
|
|
TW201705975A
(zh)
|
2015-03-18 |
2017-02-16 |
賽諾菲阿凡提斯德意志有限公司 |
第２型糖尿病病患之治療
|
|
AR105319A1
(es)
|
2015-06-05 |
2017-09-27 |
Sanofi Sa |
Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
|
|
TW201706291A
(zh)
|
2015-07-10 |
2017-02-16 |
賽諾菲公司 |
作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
|
|
JP2018523684A
(ja)
|
2015-08-18 |
2018-08-23 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
リポタンパク質アフェレーシスを受けている高脂血症の患者を治療するための抗ｐｃｓｋ９阻害抗体
|
|
JP7240004B2
(ja)
|
2017-07-27 |
2023-03-15 |
アドシア |
少なくともヒトインスリンａ２１ｇおよび食事作用性グルカゴンサプレッサーを含む水溶液注射剤の形態の組成物
|
|
KR102665710B1
(ko)
|
2017-08-24 |
2024-05-14 |
노보 노르디스크 에이/에스 |
Glp-1 조성물 및 그 용도
|
|
MX2020005916A
(es)
|
2017-12-07 |
2020-10-19 |
Adocia |
Composiciones en forma de una solución acuosa inyectable que comprende amilina, un receptor agonista de amilina o un análogo de amilina y un copoliaminoácido.
|
|
WO2019110797A1
(fr)
|
2017-12-07 |
2019-06-13 |
Adocia |
Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
|
|
BR112020011479A2
(pt)
|
2017-12-07 |
2020-11-17 |
Adocia |
composições na forma de uma solução aquosa injetável caracterizada pelo fato de que compreende amilina, um agonista do receptor de amilina ou um análogo de amilina e um co-poliaminoácido
|
|
FR3083085B1
(fr)
*
|
2018-06-29 |
2020-10-02 |
Adocia |
Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
|
|
MA54861A
(fr)
|
2019-01-31 |
2021-12-08 |
Regeneron Pharma |
Anticorps anti-récepteur de l'il6 pour traiter l'arthrite idiopathique juvénile
|
|
SG11202111742QA
(en)
|
2019-04-24 |
2021-11-29 |
Sanofi Biotechnology |
Methods of diagnosis and treatment of rheumatoid arthritis
|
|
CA3142710A1
(en)
|
2019-06-04 |
2020-12-10 |
Sanofi Biotechnology |
Compositions and methods for treating pain in subjects with rheumatoid arthritis
|
|
JP7761567B2
(ja)
*
|
2020-02-18 |
2025-10-28 |
ノヴォ ノルディスク アー／エス |
医薬製剤
|
|
JP7731153B2
(ja)
*
|
2021-01-19 |
2025-08-29 |
江▲蘇▼普莱医▲藥▼生物技▲術▼有限公司 |
抗菌ペプチド液体組成物およびその製剤
|
|
TWI880227B
(zh)
*
|
2022-05-30 |
2025-04-11 |
丹麥商西蘭製藥公司 |
澱粉素類似物之液體調配物
|